biotech / news / / CNBC
Corvus Pharmaceuticals stock is looking like a steal, Goldman Sachs says.
Goldman Sachs initiated coverage of Corvus Pharmaceuticals with a buy rating and $40 price target.
KEY POINTS
- Corvus is developing soquelitinib, a non-steroidal oral drug for atopic dermatitis treatment.
- Soquelitinib showed positive results in 75% of early-stage clinical trial participants as of January 2024.
- The global market for atopic dermatitis treatments is projected to reach over $24 billion by 2035.
- All seven analysts covering Corvus stock currently have a buy or strong buy rating.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →